Journal Oncology Times
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Researchers Find New Mechanism of Chemotherapy Resistance in TNBC
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0425Published: April 2025Expires: 3/31/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Researchers Find New Mechanism of Chemotherapy Resistance in TNBC ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0425Published: April 2025Expires: 3/31/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Imlunestrant Improves Progression-Free Survival in Some Patients With Advanced Breast Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0325Published: March 2025Expires: 2/28/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Imlunestrant Improves Progression-Free Survival in Some Patients With Advanced Breast Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0325Published: March 2025Expires: 2/28/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Promising Results for Combined Therapy in Unresectable Esophageal Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0225Published: February 2025Expires: 1/31/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Esophageal CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Promising Results for Combined Therapy in Unresectable Esophageal Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0225Published: February 2025Expires: 1/31/2027Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Esophageal CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Promising Results for Advanced CML Patients Treated With Novel Three-Drug Combination
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0125Published: January 2025Expires: 12/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Chronic Myeloid LeukemiaMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Promising Results for Advanced CML Patients Treated With Novel Three-Drug Combination ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0125Published: January 2025Expires: 12/31/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Chronic Myeloid LeukemiaMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Use of HCT for Hematologic Cancers Across Patient Groups
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT1224Published: December 2024Expires: 11/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Use of HCT for Hematologic Cancers Across Patient Groups ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN1224Published: December 2024Expires: 11/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyMedia: